Early ecological changes in intestinal microbiota with the long-acting GLP-2 analog apraglutide in short bowel syndrome.

What Was Tested

Researchers studied Teduglutide (GLP-2 analog) in this phase 2 clinical trial publication.

Short bowel syndrome with intestinal failure (SBS-IF) is a rare, severe organ failure condition requiring long-term parenteral support.

The researchers aimed to elucidate the effects of apraglutide, a novel long-acting glucagon-like peptide-2 (GLP-2) analog, on the gut microbiome in SBS-IF-CiC.

Who Took Part

The abstract describes 2 adults taking part.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

Analyses included mucosa-associated and fecal microbiota, fecal parameters, and fermentation metabolites.

How the Study Was Run

In design terms this was an open-label and multicenter study.

Everyone knew when Teduglutide (GLP-2 analog) was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Running at several centres spread the Teduglutide (GLP-2 analog) study over different clinics and patient groups.

Duodenal, distal small bowel and sigmoid colon biopsies, fecal- and plasma samples were collected over time.

For baseline comparison, duodenal and sigmoid colonic biopsies from 20 controls (10 per region) were collected.

What Was Measured

PubMed files the paper under topics including Colon, Feces, Gastrointestinal Microbiome, Glucagon-Like Peptide 2 and Short Bowel Syndrome.

Author keywords: Apraglutide, Colon-in-continuity, GLP-2 analogs and Microbiota.

What This Means in Plain Language

The paper is an open-label and multicenter study of Teduglutide (GLP-2 analog) in 2 adults.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2026 (Clinical nutrition ESPEN), a journal based in England.

More context: the Teduglutide (GLP-2 analog) compound page, all human trials.